AKRO•benzinga•
Akero Therapeutics Announces Phase 2b HARMONY Study Met Primary Endpoints For Both 50mg And 28mg EFX Dose Groups; Study Also Met Key Secondary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga